Daily Intelligence Brief
Depo-Provera MDL Absorbs 237 New Complaints As Meningioma Claims Accelerate
The Depo-Provera Products Liability Litigation (MDL 3140) (N.D. Fla., Judge M. Casey Rodgers) recorded 237 new filings in the past day. Nigh Goldenberg Raso Vaughn PLLC (46 filings), OnderLaw LLC (31), and Driscoll Firm LLC (30) are driving the coordinated filing surge. The docket now includes cases such as Henson v. Pfizer Inc. (3:26-cv-02499) and Henderson v. Pfizer Inc. (3:26-cv-02647), all alleging Pfizer's contraceptive injection causes meningioma brain tumors. This filing volume follows Judge Rodgers' March 6, 2026 case management order establishing a 180-day fact discovery track and setting the first bellwether selection conference for September 2026. The pace suggests plaintiffs' counsel are racing to beat any potential statute of limitations defenses while building inventory for global settlement leverage.Social Media Addiction Trial Deadlocked As Jury Reports Consensus Difficulty
A California federal jury hearing the first bellwether trial in MDL 3047 (N.D. Cal., Judge Yvonne Gonzalez Rogers) informed the court on March 23, 2026, that it is struggling to reach consensus, raising the prospect of a mistrial in the closely watched school district case against Meta Platforms. The trial, which began in February 2026, represents the leading edge of hundreds of claims alleging Instagram and Facebook's algorithm design causes youth mental health harms. A hung jury would reset the litigation timeline and complicate settlement positioning ahead of the August 6, 2026 state AG bellwether. Judge Gonzalez Rogers has not yet indicated whether she will instruct the jury to continue deliberations or declare a mistrial.Dow Chemical Reaches PFAS Settlement With EPA In Consent Decree
Dow Chemical Company entered into a consent decree with the EPA on March 24, 2026, resolving enforcement actions related to unauthorized PFAS releases, a development that carries immediate implications for liability defenses in ongoing PFAS contamination litigation. The settlement comes as MDL 2873 (AFFF) and MDL 2666 (PFAS) defendants face mounting pressure from municipal water authorities and individual plaintiffs. While the decree's terms remain sealed, the admission of unauthorized releases undermines industry-wide arguments that PFAS discharges were historically permitted and unregulated. Plaintiffs' counsel in the AFFF docket are expected to cite the decree in upcoming summary judgment briefing as evidence of knowing environmental contamination.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
